2004-2013年美国参保成人尿失禁神经调节治疗趋势
本研究利用Optum私营保险和Medicare 5%样本数据,分析2004-2013年成人尿失禁神经调节治疗趋势。结果显示骶神经调节在女性和男性中均稳步增长,女性中患病率从0.1%-0.2%升至0.5%-0.6%,胫后神经刺激自2011年起增长,膀胱化学去神经术保持稳定。
要点
- 骶神经调节在尿失禁患者中逐年增加,但总体仍不常见。
- 女性骶神经调节患病率从2004年0.1%-0.2%升至2013年0.5%-0.6%。
- 胫后神经刺激自2011年有保险理赔后出现增长。
核心结论
- 2004至2013年间骶神经调节治疗尿失禁虽不常见但持续增长,胫后神经刺激自2011年起增长,神经调节在尿失禁治疗中作用渐增。
研究设计与样本
- 分析按年龄、种族/民族和地理区域分层,分别评估男性和女性尿失禁相关神经调节手术的患病率。
主要发现
- 几乎所有神经调节手术均在门诊进行。
- 女性和男性骶神经调节手术从2004年至2013年稳步增长,女性手术量多于男性。
- 女性尿失禁患者中骶神经调节患病率从2004年的0.1%-0.2%增至2013年的0.5%-0.6%。
- 胫后神经刺激在2011年至2013年间出现增长。
- 膀胱化学去神经术(A型肉毒毒素)联合其他注射手术(包括尿道填充)的趋势保持稳定。
临床怎么用
- 神经调节在尿失禁治疗中的应用逐渐增多,临床医生可关注骶神经调节和胫后神经刺激的适用患者。
- 膀胱化学去神经术与其他注射手术合并分析,其单独趋势尚不明确,需未来研究单独评估。
局限性
- 膀胱化学去神经术与其他注射手术合并,无法区分其单独趋势。
- 胫后神经刺激的特异性保险理赔自2011年才可用,可能影响此前趋势评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine US trends in neuromodulation for urinary incontinence (UI) treatment from 2004 to 2013. METHODS: This study utilized 2 data sources: the Optum© de-identified Clinformatics® Data Mart Database for privately insured adults aged 18-64 years with a UI diagnosis (N≈40,000 women and men annually) and the Medicare 5% Sample for beneficiaries aged ≥65 years with a UI diagnosis (N≈65,000 women and men annually). We created annual cross-sectional cohorts and assessed prevalence of UI-related neuromodulation procedures among men and women separately from 2004 to 2013. Analyses were conducted overall and stratified by age, race/ethnicity, and geographic region. RESULTS: Nearly all neuromodulation procedures occurred in outpatient settings. Sacral neuromodulation (SNM) procedures for UI in both women and men grew steadily from 2004 to 2013, with more procedures performed in women than men. Among women with UI, SNM prevalence grew from 0.1%-0.2% in 2004 to 0.5%-0.6% in 2013. Posterior tibial nerve stimulation (PTNS) experienced growth from 2011 to 2013. Chemodenervation of the bladder with onabotulinumtoxinA (BTX) combined with other injectable procedures (including urethral bulking) remained stable over time. CONCLUSIONS: From 2004 to 2013, SNM procedures remained relatively uncommon but increased consistently. PTNS experienced growth starting in 2011 when PTNS-specific insurance claims became available. BTX trends remain unclear; future studies should assess it separately from other injectable procedures. Neuromodulation has a growing role in UI treatment, and ongoing trends will be important to examine.
引用
- Lee UJ, Ward JB, Feinstein L, et al. National Trends in Neuromodulation for Urinary Incontinence Among Insured Adult Women and Men, 2004-2013: The Urologic Diseases in America Project. Urology. 2020. PMID: 33296698. doi:10.1016/j.urology.2020.11.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。